title: Lapatinib  and renal cell carcinoma.
abstract: BACKGROUND
  Major progress in treatment of renal cell carcinoma (RCC) has occurred in the past decade.
  
  
  METHODS
  This review reports the background on the potential implication of the EGF/EGFR pathway in RCC, the different data on EGFR positivity in RCC and results from prospective Phase II and III trials on lapatinib in RCC, along with other EGF/EGFR inhibitors.
  
  
  CONCLUSIONS
  Despite important progress and the real revolution of the past decade in treatment of RCC, treatment still remains palliative most of the time. To improve treatment, it is necessary to understand whether a specific population could be selected on a molecular feature of the tumor. Until there is better knowledge of the biology, further development of drugs such as lapatinib cannot be supported.
authors.affiliation: Hôpital Saint-Andre, Bordeaux University Hospital, Bordeaux University, Department of Medical Oncology, Bordeaux, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Bernhard
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D004815:Epidermal Growth Factor; D066246:ErbB Receptors